Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Diabetes
•
Gastroenterology
•
Neurology
•
Autonomic Neurology
•
Endocrinology
•
Neuro-Gastroenterology
•
Gastrointestinal Functional & Motility Disorders
•
Primary Care
Do 5HT4 agonists such as Metoclopramide actually lead to improvement in symptoms for patients with diabetes related gastroparesis?
Related Questions
How do you counsel patients on the use of compounded weight loss medications?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
What patient specific factors outside of health insurance coverage do you use to decide which GLP1 R agonist or dual agonist therapy to start in patients with diabetes?
Do you recommend up-titrating the Metformin dose of patients with T2DM who are at goal A1c in order to decrease their risk of diabetes-related delirium?
Is there a role for intermittent fasting as part of the management of a patient with long-standing type 2 diabetes and consistently poor glycemic control despite maximal therapy?
Do you avoid empagliflozin in patients with history of amputation?
